PMID- 33383486
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231110
IS  - 1936-5233 (Print)
IS  - 1936-5233 (Electronic)
IS  - 1936-5233 (Linking)
VI  - 14
IP  - 2
DP  - 2021 Feb
TI  - Efficacy and safety of apatinib for the treatment of AFP-producing gastric 
      cancer.
PG  - 101004
LID - S1936-5233(20)30496-4 [pii]
LID - 10.1016/j.tranon.2020.101004 [doi]
LID - 101004
AB  - BACKGROUND: Alpha-fetoprotein-producing gastric cancer (AFPGC) poses a 
      therapeutic challenge worldwide because of its poor prognosis. This study aimed 
      to evaluate the efficacy and safety of antiangiogenic drug apatinib in advanced 
      AFPGC in a real-world setting. METHODS: From September 2015 to December 2017, 
      twenty-one patients identified with AFPGC from the clinical trial AHEAD-G202, an 
      open-label, prospective, multicenter, non-interventional study of apatinib for 
      advanced metastatic gastric cancer, were enrolled to perform this analysis. 
      Patients received oral apatinib as monotherapy or combination therapy. A 
      treatment cycle was defined as 28 days. The primary outcome was progression-free 
      survival (PFS) and overall survival (OS), and the secondary outcomes included 
      safety, objective response rate (ORR), and disease control rate (DCR). RESULTS: 
      Twenty patients were evaluated for the apatinib efficacy analysis. The ORR of 
      apatinib was 10%, whereas the DCR was 70%. The median PFS was 3.5 months 
      [95%confidence interval (CI): 2.34-4.66]. The median OS was 4.5 months (95%CI: 
      3.49-5.51). Median OS of AFPGC patients without carcinoembryonic antigen (CEA) 
      elevation achieved 30.8 months. CEA elevation was considered to be a potential 
      independent predictive factor for OS (P = 0.030) and PFS (P = 0.047) by the 
      analysis of multivariate analysis. The most common grade 3 to 4 adverse events 
      (AEs) were hypertension (4.8%), hand-foot syndrome (4.8%), anorexia (4.8%), and 
      vomiting and nausea (4.8%). CONCLUSION: Apatinib showed promising efficacy and an 
      acceptable safety profile in patients with advanced AFPGC. Antiangiogenic therapy 
      may be a good strategy for the treatment of AFPGC as a rare sub-type of gastric 
      cancer. TRIAL REGISTRATION: AHEAD-G202 (NCT02668380).
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Li, Ningning
AU  - Li N
AD  - Department of Oncology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
FAU - Bai, Chunmei
AU  - Bai C
AD  - Department of Oncology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.
FAU - Zhang, Ruixing
AU  - Zhang R
AD  - Department of Gastroenterology, The Fourth Hospital of Hebei Medical University, 
      Shijiazhuang 050071, China.
FAU - Ma, Liwen
AU  - Ma L
AD  - Department of Tumor Chemotherapy and Radiology, Peking University Third Hospital, 
      Beijing 100191, China.
FAU - Ren, Xiubao
AU  - Ren X
AD  - Department of Biotherapy, Tianjin Medical University Cancer Institute and 
      Hospital, Tianjin 300060, China.
FAU - Zhang, Junping
AU  - Zhang J
AD  - Department of Medical Oncology, Shanxi Academy of Medical Sciences, Shanxi Dayi 
      Hospital, Taiyuan 030032, China.
FAU - Fu, Zhanzhao
AU  - Fu Z
AD  - Department of Medical Oncology, First Hospital of Qinhuangdao, Qinhuangdao 
      066001, China.
FAU - Zhao, Lin
AU  - Zhao L
AD  - Department of Oncology, Peking Union Medical College Hospital, Peking Union 
      Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China. 
      Electronic address: wz20010727@aliyun.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02668380
PT  - Journal Article
DEP - 20201228
PL  - United States
TA  - Transl Oncol
JT  - Translational oncology
JID - 101472619
PMC - PMC7777135
OTO - NOTNLM
OT  - AFP-producing gastric cancer
OT  - Alpha-fetoprotein
OT  - Apatinib
OT  - Target therapy
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2021/01/01 06:00
MHDA- 2021/01/01 06:01
PMCR- 2020/12/28
CRDT- 2020/12/31 20:16
PHST- 2020/07/26 00:00 [received]
PHST- 2020/12/20 00:00 [revised]
PHST- 2020/12/21 00:00 [accepted]
PHST- 2021/01/01 06:00 [pubmed]
PHST- 2021/01/01 06:01 [medline]
PHST- 2020/12/31 20:16 [entrez]
PHST- 2020/12/28 00:00 [pmc-release]
AID - S1936-5233(20)30496-4 [pii]
AID - 101004 [pii]
AID - 10.1016/j.tranon.2020.101004 [doi]
PST - ppublish
SO  - Transl Oncol. 2021 Feb;14(2):101004. doi: 10.1016/j.tranon.2020.101004. Epub 2020 
      Dec 28.